中粮生物科技股份有限公司2026年第一季度财报：营收下降11.55%，净利润亏损1.21亿元

中粮生物科技2026年第一季度业绩详细解读

一、业绩表现亮点与关键数据

2026年第一季度，中粮生物科技股份有限公司（000930）公布了一份低于市场预期的财报。以下为投资者需重点关注的核心信息：

营业收入大幅下滑：公司本期实现营业收入38.79亿元，同比下降11.55%。
净利润巨幅亏损：归属于上市公司股东的净利润为-1.21亿元，同比暴跌399.62%，而去年同期为盈利4053万元。
扣非净利润进一步恶化：扣除非经常性损益后的净利润为-8578.38万元，同比大幅下滑712.43%。
经营现金流压力显著：经营活动产生的现金流量净额为-9.32亿元，同比下降263.49%。
基本每股收益为-0.0654元，稀释每股收益同为-0.0654元，均出现大幅亏损。
加权平均净资产收益率为-1.16%，同比回落1.54个百分点。
资产总额同比增长5.33%，达到176.61亿元。
归属于母公司所有者权益为104.05亿元，较年初减少1.94%。

二、影响业绩的主要因素

营业收入和成本同步下滑：收入、成本均较去年同期下降，毛利空间收窄，整体盈利能力下降。
投资收益大幅减少：投资收益为-2745.41万元，较去年同期的3210万元大幅减少，主因衍生品收益下滑。
研发投入锐减：研发费用为1741.67万元，同比大降67.69%，表明公司在创新和技术升级方面投入力度减弱，可能影响未来竞争力。
财务费用下降：财务费用同比减少40.6%，主因汇兑收益增加。
其他收益增加：其他收益同比增长69.38%，主要因增值税加计扣除金额增加。
现金流状况恶化：销售回款现金流大幅减少，导致经营活动现金流净额大幅为负。
外币报表折算差额大幅波动：本期外币财务报表折算差额为-8369.0万元，上年同期为正308万元，显示公司外汇波动风险加大。

三、非经常性损益影响

本期非经常性损益为-3565.83万元，主要包括政府补助372.38万元、金融资产公允价值变动损失3954.57万元等。非经常性损益对公司净利润形成较大负面影响。

四、股东结构与持股变动

公司股东结构较为稳定，COFCO Bio-chemical Investment Co., Ltd.持股比例为47.58%，为控股股东。大耀香港有限公司持股0.82%，其余为自然人及机构投资者。
前十大股东持股情况无重大变化，未见持股集中度明显变化。

五、资产负债表及现金流动性分析

流动资产总计69.97亿元，较年初增长。
存货大幅增长至27.8亿元，或反映前期采购或销售不畅。
短期借款大幅增加至25.05亿元，显示短期偿债压力上升。
合同负债较年初大幅增长，表明预收款项增加。
期末现金及现金等价物余额为17.46亿元，较年初下降。

六、投资者需关注的风险与机会（可能影响股价）

业绩大幅亏损、现金流大幅流出、主营业务毛利水平下滑、投资收益锐减均为显著负面信号，极有可能对公司股价构成下行压力。
短期借款和合同负债的增加，反映公司短期资金压力与经营不确定性上升。
公司研发投入大幅缩减，或影响未来产品竞争力与盈利能力，需持续关注。
汇率波动带来的外汇损失显著，投资者需防范外部环境变化对公司业绩的进一步冲击。

七、结论

总体来看，中粮生物科技2026年第一季度业绩出现了大幅亏损，现金流状况恶化，投资收益大幅下滑，研发投入锐减，短期偿债压力上升等问题。这些因素均为重大负面信号，投资者需高度警惕相关风险，股价或将面临压力。
短期内建议投资者密切关注公司后续的业绩修复能力、现金流改善措施以及外部环境影响。

免责声明： 本文仅为信息披露解读，不构成任何投资建议。股市有风险，投资需谨慎。具体投资决策请以公司公告及权威信息为准。

English Version

Detailed Analysis of COFCO Biotech Q1 2026 Financial Results

1. Key Highlights and Financial Data

COFCO Biotech (000930) released a Q1 2026 report significantly below market expectations. Key information for investors:

Sharp Drop in Revenue: Revenue was RMB 3.879 billion, down 11.55% year-on-year.
Major Net Loss: Net profit attributable to shareholders was -RMB 121 million, a plunge of 399.62% vs. a profit of RMB 40.53 million last year.
Further Drop in Core Profit: Net profit excluding non-recurring gains/losses was -RMB 85.78 million, down 712.43% year-on-year.
Operating Cash Flow Pressures: Net operating cash flow was -RMB 931 million, down 263.49% year-on-year.
Basic and Diluted EPS both -0.0654 yuan, deep in the red.
Weighted average ROE was -1.16%, down 1.54 percentage points year-on-year.
Total assets rose 5.33% to RMB 17.66 billion.
Shareholder equity fell 1.94% to RMB 10.41 billion.

2. Main Factors Affecting Performance

Simultaneous Decline in Revenue and Cost: Gross profit margin narrowed, overall profitability dropped.
Plunge in Investment Income: Investment income was -RMB 27.45 million vs. a gain of RMB 32.1 million last year, mainly due to lower derivative returns.
Sharp Cut in R&D Expenses: R&D expenses fell 67.69% to RMB 17.42 million, suggesting less investment in innovation and future competitiveness.
Lower Finance Costs: Finance expenses dropped 40.6%, mainly due to higher FX gains.
Other Income Up: Other income rose 69.38% due to higher VAT credits.
Cash Flow Conditions Worsened: Cash from sales collections dropped sharply, leading to negative operating cash flow.
Significant FX Losses: FX translation difference was -RMB 83.69 million (vs. +RMB 3.08 million last year), highlighting rising FX risk.

3. Non-recurring Items

Non-recurring loss was RMB 35.66 million, including government subsidies, fair value loss on financial assets, and more. Non-recurring items further worsened net profit.

4. Shareholding Structure

COFCO Bio-chemical Investment Co., Ltd. holds 47.58% (controlling shareholder). Other holdings stable, with no major changes in top 10 shareholders.

5. Balance Sheet and Liquidity

Total current assets at RMB 6.997 billion, up from the start of the year.
Inventories rose sharply to RMB 2.78 billion, possibly reflecting prior procurement or slow sales.
Short-term borrowing jumped to RMB 2.505 billion, raising short-term debt pressure.
Contract liabilities (advance receipts) increased significantly.
Ending cash and equivalents at RMB 1.746 billion, down from the start of the year.

6. Market-Sensitive Risks and Opportunities

Major loss, negative cash flow, narrowing margins, and shrinking investment income are all substantial negatives that could pressure the stock price.
Rising short-term debt and contract liabilities signal increased operating uncertainty.
Sharp cut in R&D spending could hurt future competitiveness and profitability.
Significant FX losses mean the company is exposed to currency risk.

7. Conclusion

Overall, COFCO Biotech posted a major loss, worsening cash flows, declining investment income, reduced R&D and higher short-term debt in Q1 2026—strong negative signals that could put downward pressure on the share price. Investors are advised to closely watch the company’s recovery efforts, cash flow improvement measures, and exposure to external risks.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Please refer to official disclosures and consult professional advisors before making investment decisions.